ATAC21
ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate[1].
Product Specifications
CAS Number
2101204-23-1
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/atac21.html
Solubility
10 mM in DMSO
Smiles
O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])OP(O)(OC[C@]3([H])[C@@]([C@H]([C@H](N4C5=C(C(N=C(N5)N)=O)N=C4)O3)O)([H])OP(O)(OC2)=O)=O)N6C7=NC=NC(NC(CCOCCOCCOCCOCCNC(CCN8C(C=CC8=O)=O)=O)=O)=C7N=C6
Molecular Formula
C38H50N12O21P2
Molecular Weight
1072.82
References & Citations
[1]Peter Armstrong Thompson, et al. Tumor targeting conjugates and methods of use thereof. WO2018140831A2.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog